V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 1

Conditions: Staphylococcal Infection

Treatments: Biological: Placebo; Biological: V710

Study type: Interventional

Funder types: Industry

Identifiers

NCT00735839

V710-006

2008_017

Details and patient eligibility

About

This study is to evaluate the safety and immunogenicity of V710 in Japanese male subjects.

Enrollment: 40 patients

Sex: Male

Ages: 20 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Generally Good Physical Health

Exclusion criteria

• Received V710 Vaccine, Any Other Investigational S. Aureus Vaccine, Or Investigational S. Aureus Antibodies Before
• Temperature Of Equal/Greater Than 100.4 Degrees F(38 Degrees C) Within The Past 48 Hours

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

40 participants in 2 patient groups, including a placebo group

V710

Experimental group

Description:

V710 vaccination (60 mcg) single dose on Day 1

Treatment:

Biological: V710

Placebo

Placebo Comparator group

Description:

Placebo single dose on Day 1

Treatment:

Biological: Placebo